119 related articles for article (PubMed ID: 9061062)
21. Mucinous markers in breast cancer.
Seregni E; Botti C; Massaron S; Martinetti A; Ferrari L; Molteni SN; Bombardieri E
Tumori; 1997; 83(2):550-1. PubMed ID: 9226018
[No Abstract] [Full Text] [Related]
22. Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen.
Klein O; Linn S; Davidson C; Hadary A; Shukha A; Zidan J; Eitan A; Kook AI
Breast; 2002 Dec; 11(6):478-83. PubMed ID: 14965713
[TBL] [Abstract][Full Text] [Related]
23. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer.
Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF
Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
25. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract][Full Text] [Related]
26. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
27. Serum (circulating) tumor markers for breast cancer.
Hayes DF
Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
[TBL] [Abstract][Full Text] [Related]
28. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
[TBL] [Abstract][Full Text] [Related]
29. Response of human lymphocytes to PHA and tumour-associated antigens as detected by fluorescence polarization.
Balding P; Light PA; Preece AW
Br J Cancer; 1980 Jan; 41(1):73-85. PubMed ID: 6153900
[TBL] [Abstract][Full Text] [Related]
30. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
31. Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients.
Abd-Elsalam EA; Ismaeil NA
Med Oncol; 2014 Nov; 31(11):285. PubMed ID: 25316266
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43.
Reinerová M; Veselovská Z; Ausch C; Rosen HR
Neoplasma; 1996; 43(6):363-6. PubMed ID: 8996559
[TBL] [Abstract][Full Text] [Related]
33. Identification of women with early breast cancer by analysis of p43-positive lymphocytes.
Auerbach L; Hellan M; Stierer M; Rosen AC; Ausch C; Obwegeser R; Kubista E; Wolf G; Rosen HR; Panzer S
Br J Cancer; 1999 May; 80(5-6):874-8. PubMed ID: 10360668
[TBL] [Abstract][Full Text] [Related]
34. Changes in the structuredness of cytoplasmic matrix (SCM) in human lymphocytes induced by PHA and cancer basic protein as measured in single cells.
Cercek L; Cercek B
Br J Cancer; 1976 May; 33(5):539-43. PubMed ID: 1276032
[TBL] [Abstract][Full Text] [Related]
35. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
Bjerner J; Norum LF; Nilsson O; Nustad K
Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
[TBL] [Abstract][Full Text] [Related]
36. [Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer].
Ammon A; Eiffert H; Alhusen R; Weber M; Rümelin B; Groh E; Bartsch H; Marschner N; Nagel GA; Krieger G
Onkologie; 1990 Jun; 13(3):210-4. PubMed ID: 2204009
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer mucin: an automated assay to detect mucus glycoproteins.
Bonfrer JM; de Graaf HM; Nooijen WJ
Tumour Biol; 1992; 13(3):162-7. PubMed ID: 1626180
[TBL] [Abstract][Full Text] [Related]
38. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
39. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
Kopczyński Z; Thielemann A
Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
[TBL] [Abstract][Full Text] [Related]
40. Detection of breast cancer from blood through analysis of lymphocyte fluorescent intensity using MUC1 antigen.
Armon-Omer A; Hadary A; Hilu G; Tayar BE; Keren T; Sharabi-Nov A; Bickel A; Klein O
Breast Cancer; 2015 Nov; 22(6):626-33. PubMed ID: 24696421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
